Skip to main content

A colon cancer study - CRC10

Using cancer cells in the blood to determine the type of chemotherapy that will benefit patients who have had surgery for colon cancer
Disease Site
Gastro-Intestinal Clinical Trials
Trial Code
CRC.10 ǀ NCT 05174169
Trial Status
Open to patient enrollment

What is the purpose of this study?

The purpose of this study is to test if we can determine what kind of chemotherapy to offer patients based on whether or not circulating tumour DNA (ctDNA) is found in a blood test taken after surgery for colon cancer.

Why is this study important?

Using ctDNA testing to determine what kind of chemotherapy to use is a new approach. This approach seems promising, but it is not clear if it can offer better results than standard treatment.

Who can participate in this study?

This trial is for:

  • Patients aged 18 or more
  • Patients with confirmed Stage II or III colon cancer
  • Patients with recent surgical treatment for colon cancer
  • Patients who will be offered the standard post-surgery treatment options

This trial is not for:

  • Patients with other cancer diagnoses within 5 years
  • Patients with multiple primary colon cancers
  • Patients with evidence of metastatic disease
  • Patients who have had any previous treatment for colorectal cancer
What are the risks?
  • If you choose to take part in this study, there is a risk that the new method of choosing your treatment may not be as good as the standard treatment. There is also a risk that you could have more side effects from more intensive chemotherapy treatment if that is recommended for you. Some of the most common side effects that the study doctors know about are: numbness/tingling, nausea, infection and hair loss. You will find details of all side effects in the consent document.
What can I expect?
  • If you choose to take part in this study, you will be entered into the trial and first have a blood test to see if you have ctDNA in your blood. If the test result is positive, you will then be randomly placed in one of two groups to receive either standard or intensified chemotherapy treatment. If the test result is negative, you will then be randomly placed in one of two other groups to receive either standard chemotherapy treatment or proceed with observation and monitoring only.

How can I find out more or join the study?

Talk to your cancer doctor if you are considering joining this study. You can share summaries like this with them and ask if they think joining the trial may be a good option for you.

Before you join this study, you will be asked to review an Informed Consent document which will tell you more about why the research is being done and your role as a participant. You will have an opportunity to discuss anything that is not clear and ask any questions you have.

Joining this study is entirely up to you and you can decide to leave at any time without giving a reason. Your decision to join or leave the trial will not affect your standard medical care.

The CRC.10 study is currently enrolling patients at cancer centres in Canada. For a full list of participating cancer centres please visit www.clinicaltrials.gov and search using NCT05174169.

https://clinicaltrials.gov/ct2/show/NCT05174169

Use this trial information for your conversation with your health care team

Participating centres
  • Regional Health Authority B, Zone 2 Saint John Regional Hospital - Saint John, NB, E2L 4L2 - Contact: Dr. James Michael
  • CIUSSS de l'Estrie - Centre hospitalier universitaire de Sherbrooke - Sherbrooke, QC, J1H 5N4 - Contact: Dr. Frederic Lemay
  • Hotel-Dieu de Quebec - Quebec City, QC, G1R 2J6 - Contact: Dr. Maxime Chenard-Poirier
  • CISSS de Chaudière-Appalaches - Levis, QC, G6V 3Z1 - Contact: Dr. Vincent Barrette
  • CIUSSS de l'Est-de-I'lle-de-Montreal Hopital Maisonneuve-Rosemont - Montreal, QC, H1T 2M4 - Contact: Dr. Mikael Soucisse
  • Centre Integre Universitaire De Sante Et De Services CIUSSS NIM - Hopital du sacre-coeur de Montreal - Montreal, QC, H4J 1C5 - Contact: Dr. Setareh Samimi
  • The Jewish General Hospital - Montreal, QC, H3T 1E2 - Contact: Dr. Petr Kavan
  • Centre Integre de Sante et de Services Sociaux de la Monteregie-Centre - Greenfield Park, QC, J4V 2H1 - Contact: Dr. Melina Boutin
  • Ottawa Hospital Research Institute - Ottawa, ON, K1H 8L6 - Contact: Dr. Rakesh Goel
  • Niagara Health System - St. Catharines, ON, L2S 0A9 - Contact: Dr. Radhika Yelamanchili
  • Lakeridge Health Oshawa - Oshawa, ON, L1G 2B9 - Contact: Dr. Amin Kay
  • Stronach Regional Health Centre at Southlake - Newmarket, ON, L3Y 2P9 - Contact: Dr. Cynthia Luk
  • Odette Cancer Centre Sunnybrook Health Sciences Centre - Toronto, ON, M4N 3M5 - Contact: Dr. Sheron Perera
  • North York General Hospital - Toronto, ON, M2K 1E1 - Contact: Dr. Kathryn Towns
  • Grand River Regional Cancer Centre at Grand River Hospital - Kitchener, ON, N2G 1G3 - Contact: Dr. Anupam Batra
  • Verspeeten Family Cancer Centre - London, ON, N6A 5W9 - Contact: Dr. Elena Tsvetkova
  • Allan Blair Cancer Centre - Regina, SK, S4T 7T1 - Contact: Dr. Kimberly M Hagel
  • Saskatoon Cancer Centre - Saskatoon, SK, S7N 4H4 - Contact: Dr. Shahid Ahmed
  • Tom Baker Cancer Centre - Calgary, AB, T2N 4N2 - Contact: Dr. Patricia Tang
  • BCCA - Vancouver - Vancouver, BC, V5Z 4E6 - Contact: Dr. Jonathan M Loree
  • BCCA - Prince George - Prince George, BC, V2M 7E9 - Contact: Dr. Jonathan M Loree
  • BCCA - Victoria - Victoria, BC, V8R 6V5 - Contact: Dr. Nicholas Bosma